Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels

Abdi, Hibo H.; Backes, Carl H.; Ball, Molly K.; Talavera‐Barber, Maria M.; Klebanoff, Mark A.; Jadcherla, Sudarshan R.; Mohamed, Tahagod; Slaughter, Jonathan L.

doi:10.1038/s41372-021-00995-x

Cited by 6 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average mean age in all reported treatment group and control group was 27 weeks (ranging from 26 to 28 weeks). Table 1 shows the main characteristics of the included studies ( 15 , 17 , 27 – 29 , 38 – 55 ).…”

Section: Resultsmentioning

confidence: 99%

Use of Prophylactic Indomethacin in Preterm Infants: A Systematic Review and Meta-Analysis

2022

View full text Add to dashboard Cite

BackgroundProphylactic indomethacin has been widely used as an effective intervention for reducing mortalities and morbidities in preterm infants including the cardiopulmonary and neurodevelopmental morbidities such as intraventricular hemorrhage (IVH), but many studies have reported contradictory outcomes regarding its significance. Therefore, we aim to systematically review and meta-analyze the data of prophylactic indomethacin on preterm infants.MethodsOur systematic search included the following databases: Pubmed, Google Scholar, Scopus, Web of Science, The New York Academy of Medicine (NYAM), Virtual health library (VHL), and the System for Information on Grey Literature in Europe (SIGLE) to include studies that assessed the use of prophylactic indomethacin in preterm infants until 12 August 2021.ResultsThe final list of our included studies is comprised of 23 randomized trials and cohort studies. Among all the studies outcomes, significant favorable outcome was lowering the rate of PDA, surgical PDA ligation (P < 0.001) and severe IVH (P = 0.008) while no significance was recorded with BPD, pulmonary hemorrhage, intraventricular hemorrhage, necrotizing enterocolitis, intestinal perforation, mortality, and length of hospital stay.ConclusionSince the meta-analysis results regarding effectiveness of prophylactic indomethacin varied based on the study design particularly with regard to outcomes such as surgical PDA ligation and severe IVH, this warrants the need for more evidence regarding the effectiveness of prophylactic indomethacin in very low birth weight infants.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of Prophylactic Indomethacin in Preterm Infants: A Systematic Review and Meta-Analysis

2022

View full text Add to dashboard Cite

show abstract

The clinical burden of extremely preterm birth in a large medical records database in the United States: Mortality and survival associated with selected complications

Siffel

Hirst

Sarda

et al. 2022

Early Human Development

View full text Add to dashboard Cite

Prophylactic Indomethacin in Infants Born Extremely Preterm: Risks and Benefits Revisited

Clyman¹

2023

The Journal of Pediatrics

View full text Add to dashboard Cite

Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels

Abstract: OBJECTIVES:To identify the relationship between prophylactic indomethacin (PI) administration and 1) mortality and bronchopulmonary dysplasia (BPD) at 36-weeks postmenstrual age (PMA) (primary outcome), and 2) to evaluate for PI-associated acute kidney injury.

Cited by 6 publications

References 32 publications

Use of Prophylactic Indomethacin in Preterm Infants: A Systematic Review and Meta-Analysis

Use of Prophylactic Indomethacin in Preterm Infants: A Systematic Review and Meta-Analysis

The clinical burden of extremely preterm birth in a large medical records database in the United States: Mortality and survival associated with selected complications

Prophylactic Indomethacin in Infants Born Extremely Preterm: Risks and Benefits Revisited

Contact Info

Product

Resources

About